Steve Cohen’s Point72 says it has perfect U.S. compliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Celator Pharmaceuticals (CPXX) Misses Q4 EPS by 1c
March 21, 2016 8:21 AM EDTCelator Pharmaceuticals (NASDAQ: CPXX) reported Q4 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).
The following are expected milestones for VYXEOS:
3Q 2016 New Drug Application (NDA) submission1Q 2017 Marketing Authorization Application (MAA) submissionMid-2017 Prescription Drug User Fee Act (PDUFA)... More